Dianthus Therapeutics, Inc. /DE/ financial data

Symbol
DNTH on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1549% % -43%
Debt-to-equity 6.2% % 63%
Return On Equity -33% % -52%
Return On Assets -31% % -49%
Operating Margin -4558% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42,876,015 shares 45%
Common Stock, Shares, Outstanding 42,854,563 shares 46%
Entity Public Float $651,000,000 USD 1928%
Common Stock, Value, Issued $43,000 USD 48%
Weighted Average Number of Shares Outstanding, Basic 37,794,088 shares 10%
Weighted Average Number of Shares Outstanding, Diluted 37,794,088 shares 10%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $3,078,000 USD -82%
Revenue from Contract with Customer, Excluding Assessed Tax $3,078,000 USD -82%
Research and Development Expense $116,951,000 USD 79%
General and Administrative Expense $31,230,000 USD 37%
Operating Income (Loss) $140,308,000 USD -69%
Nonoperating Income (Expense) $13,963,000 USD -12%
Net Income (Loss) Attributable to Parent $126,345,000 USD -88%
Earnings Per Share, Basic -3 USD/shares -124%
Earnings Per Share, Diluted -3 USD/shares -124%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $55,984,000 USD 66%
Cash, Cash Equivalents, and Short-term Investments $54,994,000 USD
Accounts Receivable, after Allowance for Credit Loss, Current $5,000,000 USD 260%
Other Assets, Current $73,000 USD
Assets, Current $413,825,000 USD 44%
Property, Plant and Equipment, Net $185,000 USD -2.1%
Operating Lease, Right-of-Use Asset $1,306,000 USD 271%
Assets $577,445,000 USD 63%
Accounts Payable, Current $6,705,000 USD -11%
Employee-related Liabilities, Current $6,671,000 USD 66%
Accrued Liabilities, Current $15,979,000 USD 107%
Liabilities, Current $23,855,000 USD 52%
Operating Lease, Liability, Noncurrent $1,068,000 USD
Liabilities $30,991,000 USD 90%
Accumulated Other Comprehensive Income (Loss), Net of Tax $163,000 USD -76%
Retained Earnings (Accumulated Deficit) $272,297,000 USD -87%
Stockholders' Equity Attributable to Parent $546,454,000 USD 62%
Liabilities and Equity $577,445,000 USD 63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $27,630,000 USD -85%
Net Cash Provided by (Used in) Financing Activities $161,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $14,794,000 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 42,854,563 shares 46%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $12,675,000 USD -106%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56,151,000 USD 66%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $181,605,000 USD 47%
Deferred Tax Assets, Gross $0 USD
Operating Lease, Liability $1,285,000 USD 313%
Depreciation $110,000 USD 24%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $126,863,000 USD -91%
Lessee, Operating Lease, Liability, to be Paid $1,627,000 USD 396%
Property, Plant and Equipment, Gross $462,000 USD 30%
Operating Lease, Liability, Current $217,000 USD -30%
Lessee, Operating Lease, Liability, to be Paid, Year Two $314,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $268,000 USD 21%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -27%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $342,000 USD 1912%
Lessee, Operating Lease, Liability, to be Paid, Year Three $318,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $109,660,000 USD 49%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $321,000 USD
Operating Lease, Payments $100,000 USD -67%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $227,000 USD -98%
Share-based Payment Arrangement, Expense $20,733,000 USD 114%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%